[Field report] NEST is honored to take part in the #ISoOR 2023 Annual Meeting on site, teaming up with DKSH Singapore Scientific Instrumentation. The international society of organoids research (ISoOR) is a global organisation dedicated to advancing organoids research and development in its basic biology, disease modelling and precision medicine treatment. It provides a platform for academics and researchers to discuss major topics such as Organoids and Precision Medicine, Organoids and Regenerative Medicine, and Organoids and Drug Development.
On 07th August, a groundbreaking ceremony was officiated to embrace the boundless possibilities of the organoids research, and of course, an act of symbolic “金沙” (golden sand) was poured slowly down the panel where the characters of ‘ISoOR’ shimmered into sight, pushing the ceremonial opening to a climax. The day began with opening remarks welcoming the delegates to the inaugural meeting from the organisers Pharmacological Society of Singapore and Scipolis.
During the meeting, NEST and DKSH collaborated to showcase NEST's cutting-edge laboratory consumables and solutions, with the ultimate goal of optimizing research operations and empowering research expertise. NEST presented its highly sought-after product range, which included the recently launched baffled Erlenmeyer Flask, the customizable Multi-layer Cell Culture Flask, and the innovative Centrifuge Tube Closed System Solution. To further captivate visitors, NEST offered exceptional giveaway gifts to customers who visited their booth, effectively capturing the attention of numerous attendees and contributing to the dynamic ambiance of the event. The dedicated sales representatives fully immersed themselves in the energetic atmosphere, diligently attending to customers and addressing their inquiries.
Keynote speaker Professor Dean Ho began his optimism on his ‘digital avatar’ dynamic modelling ‘CURATE.AI’ which harnesses a patient’s clinical trial data, drug type, drug dose regimen, and a screened panel of cancer biomarkers to generate an individualised ‘digital avatar’ that can be used to customise that optimal dose during chemotherapy treatment – this was presented in ASCO 2023 meeting [Titled: Artificial Intelligence on Clinical Oncology: from Data to Digital Pathology and Treatment].
Chinese venture capitals such as Huaan Pu Chu Funds, CSPC Venture Capital, Grains Velly Venture Capital and Bairong Capital lead that intense round-table discussion (the investor’s perspective) on the future of organoids and if it is the right time to place a bigger bet on organoids in systems biology, bioengineering and data sciences to address real-world challenges faced off in the drug discovery and preclinical to clinical research.
Other thought-provoking discussion-filled day by various academic delegates from Singapore and China [Link]. NEST Biotechnology, co-represented by its distributor DKSH (Singapore), had been invited to participate and exhibit in this ISoOR 2023 Annual Meeting.
